Skip Navigation

Cardiovascular Research 2004 63(1):8-10; doi:10.1016/j.cardiores.2004.04.023
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thiemermann, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thiemermann, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size

Christoph Thiemermann*

Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, John-Vane Science Centre, Barts and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M6BQ, UK

*Tel.: +44-207-9826199l; fax: +44-207-2511685. Email address: c.thiemermann@qmul.ac.uk

Received 30 March 2004; revised 21 April 2004; accepted 22 April 2004

The first 10% of the full text of this article appears below.

See article by Onai et al. [6] (pages 51–59) in this issue.

Nuclear factor kappa B (NF-{kappa}B) is a transcription factor that plays a pivotal role in the induction of genes involved in physiological processes as well as in the response to injury and inflammation. The process leading to the activation of NF-{kappa}B requires phosphorylation of an inhibitor of NF-{kappa}B (I{kappa}B) by I{kappa}B kinase (IKK), resulting in degradation of I{kappa}B by the 26S proteasome. This allows the translocation of NF-{kappa}B from the cytosol to the nucleus, where the heterodimer binds to a response element in the promotor region of specific target genes. Activation of NF-{kappa}B induces gene programs leading to the transcription of factors that promote inflammation (i.e. adhesion molecules, cytokines . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
W. E. Stansfield, N. C. Moss, M. S. Willis, R. Tang, and C. H. Selzman
Proteasome Inhibition Attenuates Infarct Size and Preserves Cardiac Function in a Murine Model of Myocardial Ischemia-Reperfusion Injury
Ann. Thorac. Surg., July 1, 2007; 84(1): 120 - 125.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H.-L. Li, M.-L. Zhuo, D. Wang, A.-B. Wang, H. Cai, L.-H. Sun, Q. Yang, Y. Huang, Y.-S. Wei, P. P. Liu, et al.
Targeted Cardiac Overexpression of A20 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction
Circulation, April 10, 2007; 115(14): 1885 - 1894.
[Abstract] [Full Text] [PDF]